QLGN Insider Trading Activity and SEC Form 4 Filings
QLGN insider trading summary
No open-market insider purchases or sales of Qualigen Therapeutics, Inc. (QLGN) have been reported on SEC Form 4 in the past 12 months.
Latest QLGN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 22, 2022 | Michael S. Poirier | Chairman and CEO | Buy | $17K (30,000 @ $0.57) |
| Jun 14, 2022 | Amy S. Broidrick | President/CSO | Buy | $19K (30,000 @ $0.62) |
| Aug 19, 2021 | Kurt H Kruger | Director | Buy | $5K (4,000 @ $1.22) |
| Aug 19, 2021 | Kurt H Kruger | Director | Buy | $5K (4,000 @ $1.23) |
| Apr 26, 2021 | Amy S. Broidrick | EVP, Chief Strategy Officer | Buy | $9K (4,500 @ $2.03) |
| Apr 20, 2021 | Michael S. Poirier | Chairman, CEO & President | Buy | $20K (11,005 @ $1.80) |
| Apr 16, 2021 | Christopher L. Lotz | Vice President of Finance, CFO | Buy | $5K (2,700 @ $1.86) |
| Dec 29, 2020 | Kurt H Kruger | Director | Buy | $12K (4,000 @ $2.94) |
| Nov 23, 2020 | Kurt H Kruger | Director | Buy | $16K (4,600 @ $3.46) |
| Nov 20, 2020 | Kurt H Kruger | Director | Buy | $5K (1,400 @ $3.55) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.